Biologics in the management of IgE-mediated food allergy. What is new?

Abstract

The prevalence and the burden of food allergies (FAs) have been estimated to be increased in recent decades, particularly in urban and developed areas. In parallel, in the last decade, new treatment options have been available, including biologicals. In February 2024, the FDA approved omalizumab for IgE-mediated FA to prevent severe accidental reactions. This review provides an overview of current biologicals available on the market and the main emerging drugs under evaluation with a main focus on IgE-mediated FA. The challenge for current and near-future research in the field remains to determine the ideal candidates for each biologic treatment and to refine the therapeutic protocols.